Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Answer

Staff  |  Issue: August 2007  |  August 1, 2007

Take the Challenge…

The proper way to code this visit is 99214-25, 96413, 96415, J1745 x60-JW, 90775, J2920-, 96401, J9250 x3, 90761-59, J7130, 99214-25.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • 99214-25: Because the patient had additional diagnoses of fatigue and joint pain during a scheduled methotrexate injection and infliximab infusion, the physician performed a detailed problem history, detailed examination, and a medical decision making of moderate complexity office visit with a modifier -25 appended.
  • 96413: This drug administration code indicates the infusion was 30 minutes.
  • 96415: This drug administration code indicates the remainder of the infusion time of five minutes.
  • J1745x60-JW: The HCPCs code for infliximab (10 mg) and the amount mixed (60 x10 =600). The JW indicates that wastage existed, and it should be documented in the patient’s chart.
  • 90775: Because there was an allergic reaction to the infliximab, this IV push code was used with the methylprednisolone, sodium succinate. An initial substance/drug code was already used (96413), and this IV push code was used to indicate a new substance. It must be listed separately in addition to the code for the primary procedure.
  • J2920: Injection methylprednisolone sodium succinate, up to 40 mg.
  • 96401: Chemo, injection SC/IM drug administration code for Methotrexate sodium, 5 mg.
  • J9250 x3: Methotrexate sodium, 5 mg to 15 mg was used for this scenario so x3 is used to signify 15 mg.
  • 90761-59: Normal saline was also used to flush out the infliximab from the patients system, and this drug administration code represents each additional hour used. The -59 modifier is used to indicate that this was an additional substance for the allergic reaction.
  • J7130: Hypertonic saline solution, 50 or 100 meq, 20 cc per vial.

Note: Medicare has developed a reimbursement policy for the administration of single-use drugs or discarded biological material for both ASP and CAP drugs, effective July 1, 2007. For billing purposes, the JW modifier is used to indicate discarded medication not administered.

Share: 

Filed under:Billing/Coding Tagged with:CodingE&MEvaluation and ManagementMedical decision making

Related Articles

    New HCPCS Modifiers Replace -59 on January 1, 2015

    December 1, 2014

    Referred to as -X modifiers, they are designed to define specific subsets of -59 modifier

    Coding Corner Answer: A Quiz on Modifiers

    February 18, 2019

    Take the challenge. 1. A—Modifier -25 is defined as a significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service. It is to be placed on the E/M visit only because it attests to the payer there is…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Coding Corner Answer: March

    March 1, 2015

    Coding for chemotherapy infusion with a drug reaction

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences